Anti-Human ANGPTL3 (Evinacumab) (A510-GRP)

Angiopoietin-like protein 3 (ANGPTL3) is a glycoprotein primarily produced in the liver and plays a crucial role in lipid metabolism. It hinders the function of lipoprotein lipase (LPL) and endothelial lipase (EL) which are essential for breaking down triglycerides and phospholipids. By blocking these enzymes ANGPTL3 increases the levels of triglycerides LDL cholesterol and HDL cholesterol in the blood. Research has shown that mutations in ANGPTL3 that result in reduced function are associated with lower lipid levels and a reduced risk of coronary artery disease1-3. The monoclonal antibody REGN 1500, also known as evinacumab, targets ANGPTL3 to treat hypercholesterolemia (HoFH) a rare genetic condition characterized by extremely high cholesterol levels. Evinacumab works by inhibiting ANGPTL3, which helps break down fats and leads to a decrease in low-density lipoprotein cholesterol (LDL-C). Clinical trials have proven that evinacumab can reduce LDL-C levels by around 47% in patients, with HoFH4-7.